LayerBio

Executive Summary

LayerBio is a preclinical-stage biotechnology company developing innovative drug delivery therapies for ophthalmology. Its proprietary OcuRing™ platform is a bioerodible, sustained-release system designed to be used with standard intraocular lenses (IOLs) during cataract surgery. This technology aims to provide long-term, controlled release of therapeutics directly to the eye, potentially improving patient outcomes by reducing the need for postoperative eye drops and enhancing compliance. The company is headquartered in Lexington, Massachusetts and was founded in 2016. While still in preclinical development, LayerBio addresses a significant unmet need in cataract surgery, where current standard of care often requires patients to administer multiple topical medications postoperatively. If successful, OcuRing could become a standard adjunct to cataract surgery, offering a differentiated value proposition to surgeons and patients. The company's progress is early stage, but the platform's potential to combine drug delivery with a common surgical procedure positions it for interest from strategic partners in the ophthalmic space. LayerBio's near-term focus is likely on advancing OcuRing through preclinical studies and towards an Investigational New Drug (IND) application.

Upcoming Catalysts (preview)

• H1 2027IND Filing for Lead Program OcuRing50% success
• H2 2027Partnership or Collaboration with Ophthalmic Device or Pharma Company35% success
• H2 2026In Vivo Proof-of-Concept Data Release60% success